Pascale A Cohen

Summary

Country: France

Publications

  1. pmc A candidate molecular signature associated with tamoxifen failure in primary breast cancer
    Julie A Vendrell
    Universite de Lyon, Faculté de Pharmacie de Lyon, France
    Breast Cancer Res 10:R88. 2008
  2. doi request reprint Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways
    Sandra E Ghayad
    Universite de Lyon, France
    Int J Cancer 126:545-62. 2010
  3. doi request reprint mTOR inhibition reverses acquired endocrine therapy resistance of breast cancer cells at the cell proliferation and gene-expression levels
    Sandra E Ghayad
    Universite de Lyon, Lyon, France
    Cancer Sci 99:1992-2003. 2008
  4. doi request reprint Identification of TACC1, NOV, and PTTG1 as new candidate genes associated with endocrine therapy resistance in breast cancer
    Sandra E Ghayad
    Universite de Lyon, 69008 Lyon, France Université Lyon 1, ISPB, Faculté de Pharmacie de Lyon, 69008 Lyon, France INSERM, U590, 69008 Lyon, France
    J Mol Endocrinol 42:87-103. 2009
  5. pmc ZNF217 confers resistance to the pro-apoptotic signals of paclitaxel and aberrant expression of Aurora-A in breast cancer cells
    Aurélie Thollet
    Universite de Lyon, Lyon, France
    Mol Cancer 9:291. 2010
  6. ncbi request reprint Inhibitors of the PI3K/Akt/mTOR pathway: new hope for breast cancer patients
    Sandra E Ghayad
    Universite de Lyon, Lyon, France
    Recent Pat Anticancer Drug Discov 5:29-57. 2010

Collaborators

Detail Information

Publications6

  1. pmc A candidate molecular signature associated with tamoxifen failure in primary breast cancer
    Julie A Vendrell
    Universite de Lyon, Faculté de Pharmacie de Lyon, France
    Breast Cancer Res 10:R88. 2008
    ..Identification of such markers would be clinically useful. We attempted to identify molecular markers associated with tamoxifen failure in breast cancer...
  2. doi request reprint Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways
    Sandra E Ghayad
    Universite de Lyon, France
    Int J Cancer 126:545-62. 2010
    ..In conclusion, the combination of MAPK and PI3K inhibitors represents a promising strategy to overcome endocrine therapy resistance in ER+ breast cancer patients...
  3. doi request reprint mTOR inhibition reverses acquired endocrine therapy resistance of breast cancer cells at the cell proliferation and gene-expression levels
    Sandra E Ghayad
    Universite de Lyon, Lyon, France
    Cancer Sci 99:1992-2003. 2008
    ..Taken together, data presented herein strongly support the idea that mTOR inhibitor might be one of the promising therapeutic approaches for patients with ERalpha-positive endocrine therapy-resistant breast cancers...
  4. doi request reprint Identification of TACC1, NOV, and PTTG1 as new candidate genes associated with endocrine therapy resistance in breast cancer
    Sandra E Ghayad
    Universite de Lyon, 69008 Lyon, France Université Lyon 1, ISPB, Faculté de Pharmacie de Lyon, 69008 Lyon, France INSERM, U590, 69008 Lyon, France
    J Mol Endocrinol 42:87-103. 2009
    ..7 cells compared with their respective control MVLN cells. In conclusion, our data identify TACC1, NOV, and PTTG1 as promising new markers that could be used in the clinical management of ER-positive breast cancer patients...
  5. pmc ZNF217 confers resistance to the pro-apoptotic signals of paclitaxel and aberrant expression of Aurora-A in breast cancer cells
    Aurélie Thollet
    Universite de Lyon, Lyon, France
    Mol Cancer 9:291. 2010
    ..The precise mechanisms involved in ZNF217 pro-survival function are currently unknown, and utmost importance is given to deciphering the role of ZNF217 in cancer therapy response...
  6. ncbi request reprint Inhibitors of the PI3K/Akt/mTOR pathway: new hope for breast cancer patients
    Sandra E Ghayad
    Universite de Lyon, Lyon, France
    Recent Pat Anticancer Drug Discov 5:29-57. 2010
    ....